Baker BROS. Advisors LP Acquires New Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Baker BROS. Advisors LP purchased a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 670,751 shares of the company’s stock, valued at approximately $16,775,000. Baker BROS. Advisors LP owned approximately 0.50% of Centessa Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Foresite Capital Management VI LLC raised its stake in shares of Centessa Pharmaceuticals by 4.8% during the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock valued at $31,865,000 after acquiring an additional 60,640 shares in the last quarter. Eagle Health Investments LP bought a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $2,500,000. SG Americas Securities LLC raised its stake in shares of Centessa Pharmaceuticals by 1,017.7% during the fourth quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock valued at $6,593,000 after acquiring an additional 240,039 shares in the last quarter. Royce & Associates LP bought a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $5,999,000. Finally, Cinctive Capital Management LP bought a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $2,246,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $39.87 on Thursday. The company has a market capitalization of $6.17 billion, a price-to-earnings ratio of -22.27 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $12.30 and a 52 week high of $40.26. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The firm has a 50 day moving average of $39.65 and a 200 day moving average of $31.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Karen M. Anderson sold 41,076 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the transaction, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. The trade was a 39.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.09% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on CNTA. Wells Fargo & Company downgraded shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $35.00 to $42.00 in a research report on Monday, April 20th. Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their target price for the company from $36.00 to $40.00 in a research report on Wednesday, April 1st. Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Finally, Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective for the company. in a research note on Monday, April 13th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.